Buprenorphine

"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Descriptor ID	D002047
MeSH Number(s)	D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
Concept/Terms	Buprenorphine Buprenorphine Buprenex Buprenex Prefin Prefin Subutex Subutex Buprex Temgesic Temgésic 6029-M 6029-M 6029 M 6029M RX-6029-M RX 6029 M RX6029M Buprenorphine Hydrochloride Buprenorphine Hydrochloride Hydrochloride, Buprenorphine

Below are MeSH descriptors whose meaning is more general than "Buprenorphine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Buprenorphine [D03.132.577.249.150]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Buprenorphine [D03.605.497.150]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Buprenorphine [D03.633.400.686.150]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Buprenorphine [D04.615.723.795.150]

Below are MeSH descriptors whose meaning is related to "Buprenorphine".

Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".

Buprenorphine
Buprenorphine, Naloxone Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.

Bar chart showing 126 publications over 20 distinct years, with a maximum of 19 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2007	1	0	1
2009	3	0	3
2010	1	0	1
2011	3	0	3
2012	3	2	5
2013	4	0	4
2014	2	3	5
2015	4	0	4
2016	1	2	3
2017	2	2	4
2018	3	3	6
2019	3	2	5
2020	4	4	8
2021	10	0	10
2022	19	0	19
2023	12	0	12
2024	11	5	16
2025	4	5	9
2026	4	3	7

Below are the most recent publications written about "Buprenorphine" by people in Profiles.

Evans EA, Stopka TJ, Pivovarova E, Ryan D, Murphy SM, Jaffe K, Bernson D, Bovell-Ammon B, McCollister KE, Bianchet E, Hoskinson R, Friedmann PD. Jail-based opioid treatment implementation, outcomes, and costs: lessons learned from the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). Harm Reduct J. 2026 10 23; 23(1).

View in: PubMed
Martin R, Carpenter R, Hoadley A, Bailey A, Kang A, Rich J, Rohsenow D, Hurley L, Clarke J. Population-level benefits of correctional medications for opioid use disorder. J Subst Use Addict Treat. 2026 Dec; 191:210111.

View in: PubMed
Bailey A, Hughto JMW, Kelly PJA, Dunsiger SI, Martin RA. Patient preferences for medications to treat opioid use disorder in carceral settings: Implications for tailored implementation and service delivery. J Subst Use Addict Treat. 2026 Dec; 191:210099.

View in: PubMed
Monico LB, Bambury EA, Foreman JK, Avila M, Martin SA. Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study. J Med Internet Res. 2026 08 14; 28:e100527.

View in: PubMed
Gorman JA, Ameral VE, Abrams BE, Park D, Kaubrys MM, Khazanov GK. Contingency management for adherence to injectable medication for substance use disorders. J Subst Use Addict Treat. 2026 Nov; 190:210055.

View in: PubMed
Votaw VR, Rosen RL, Peckham AD, London Z, Philpotts LL, Weiss RD, McHugh RK, Streck JM. Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review. J Dual Diagn. 2026 Apr; 22(2):158-190.

View in: PubMed
Schoenfeld EM, Soares WE, Girardin AL, Simon C, Strokes N, Lauren N, Santana CS, Beck SA, Westafer LM. "Talk About It!" Shared Decision-Making for Methadone and Buprenorphine Initiation: Development and Preliminary Evaluation of a Conversation Aid via Community-Based Participatory Research. Acad Emerg Med. 2026 03; 33(3):e70256.

View in: PubMed
Wolkowicz NR, Musket CW, Sofuoglu M, Reilly ED, MacLean RR, Portnoy GA. U.S. Military Veteran Perspectives on Barriers and Facilitators to Medication Treatment for Opioid Use Disorder. Subst Use Misuse. 2026; 61(6):858-870.

View in: PubMed
Rottapel RE, Stopka TJ, Friedmann PD, Hoskinson RA, Englander D, Calhoun N, Senst T, Gudas C, Koutoujian PJ, Farabee D. A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail. Addict Sci Clin Pract. 2025 10 27; 20(1):88.

View in: PubMed
Ostrowski SJ, Adkins A, Goldfarb D, Kukowski M, Stratton D, Barton DJ, Pizon AF. Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study. Clin Toxicol (Phila). 2025 Nov; 63(11):897-905.

View in: PubMed

People

Explore

Similar Concepts

Top Journals